



Express Mail No. **EV 913 329 404 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Koenig et al.

Confirmation No.: 1503

Serial No.: 10/524,134

Art Unit: 1644

Filed: February 11, 2005

Examiner: Crowder, Chun

For: FcγRIIB-SPECIFIC ANTIBODIES
AND METHODS OF USE THEREOF

Attorney Docket No.: 11183-003-999

AMENDMENT UNDER 37 C.F.R. § 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated April 10, 2006 (the "Office Action"), and in accordance with Rule 111 of the Rules of Practice, please enter the following amendments and consider the following remarks. Applicants submit herewith (1) a Substitute Specification pursuant to 37 C.F.R. § 1.125; (2) Exhibit A, Statement of Attorneys for Applicants Regarding the Permanence and Availability of Deposited Microorganisms (including copy of Receipt of Deposit); (3) Exhibit B, a copy of Budde et al., 1995, "Specificity of CD32 mAb for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells, in Leucocyte Typing V, White Cell Differentiation Antigens, Vol. I, (eds. Schlossman et al.), 828-832, previously submitted as reference C09 in the Information Disclosure Statement of July 15, 2005 ("July 15 IDS"); (4) Exhibit C, Declaration of Dr. Scott Koenig pursuant to 37 C.F.R. § 1.132; (5) Exhibit D, a copy of Tam et al., 1995, Allergy 59:772-780, previously submitted as reference C58 in the July 15 IDS; (6) a supplemental Information Disclosure Statement with a List of References Cited and copies of References B10-B14 and C72-C82; (7) a Transmittal of Sequence Listing; (8) a Sequence Listing in paper and computer readable form; (9) a return copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures; and (10) a Petition for Extension of Time (in duplicate) for three (3) months for responding to the Office Action, from July 10, 2006 up to and including October 10, 2006. It is requested that the enclosed documents be entered in the file of the above-identified application.

It is believed that there is no fee required for filing of this response other than that authorized in the Petition for Extension of Time and Supplemental Information Disclosure

Statement submitted concurrently herewith; however, in the event that a fee is required, please charge Jones Day Deposit Account No. 50-3013.

Applicants respectfully request that the amendments and remarks made herein be entered and made of record of the instant application.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims begin on page 4 of this paper.

Remarks begin on page 14 of this paper.